Lipid Nanoparticles for Topical and Transdermal Delivery of Pharmaceuticals and Cosmeceuticals

The document from 2018 reviews the application of lipid nanoparticles, specifically solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), for topical and transdermal delivery of drugs and cosmeceuticals. It outlines the advantages of these systems, such as enhanced physical stability, controlled release, and improved biocompatibility, and their ability to protect light-sensitive ingredients. The document also covers the structure and function of human skin, the importance of the epidermal barrier, and skin diseases like hyperhidrosis and acne, noting that lipid nanoparticles can limit systemic absorption of actives. It discusses acne and alopecia, detailing their pathogenesis and treatment options, and emphasizes the importance of early diagnosis in conditions like scarring alopecia. The document also explains drug penetration routes through the skin, the concept of dermatopharmacokinetics for understanding drug action in the stratum corneum, and the FDA's recommendation for its use in bioequivalence studies. It mentions the physicochemical properties required for effective skin drug delivery and reviews the use of lipid nanoparticles in clinical settings for conditions like fungal infections and contact dermatitis. Lastly, it reports on a study where an LF-SQ cream with lipid nanoparticles improved skin moisture and reduced wrinkles after 8 weeks of use, concluding that SLNs and NLCs are significant advancements in topical and transdermal product development, with a promising future in both pharmaceutical and cosmeceutical industries.